Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Commercializing Cancer Vaccines: A Decision Support Tool for
Optimizing the Pipeline
Published on October 2010

Report Summary

This report comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99
investigators, from Ceased to Marketed. The report extensively analyses their 94 identified drug targets, organized into 91 drug target
strategies, and assesses them in 42 different cancer indications. BioSeeker has applied its unique drug assessment methodology to
stratify the cancer vaccine pipeline and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of cancer vaccine drugs is split between the 46% which have unique drug target strategies and
the other half which have head-to-head target competing vaccine drugs in 20 different clusters. The latter has a competing ratio which
is almost two and half time higher than the comparable average of cancer vaccine drugs. Contributing to this fact is heavily utilized
drug target strategies like: ERBB2, TERT and MUC1.

* Nine out of ten drug target strategies in Phase III development are new to cancer vaccine drugs, whereas the greatest number of
new target strategies are found in Preclinical- and Phase II development.

* Protein and gene therapy are the dominating compound strategies of cancer vaccine drugs, which represent half of the entire
pipeline. Cell therapy based cancer vaccines has the least unique target strategy portfolio compared to that of other compound
strategies of cancer vaccine drugs.

* The highest numbers of described target strategies among cancer vaccine drugs are found in breast cancer, colorectal cancer,
melanoma and prostate cancer. Cancer vaccine drugs are experiencing targeting competition in one out of every three cancer
indications described, and more so in cervical cancer/dysplasia, prostate cancer, head and neck cancer and breast cancer.

* The highest number of described drug target strategies of cancer vaccine drugs belongs to Advaxis, Cancer Research Technology,
Dendreon and Inovio. However, when looking at the highest number of developmental projects Celldex Therapeutics, Cell Genesys,
Advaxis and Dendreon take the lead.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development
strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and
manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and
portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are
aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing
and new business opportunities

Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline (From Slideshare) Page 1/13


* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies
* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own
organization. The report will also be an important part of creating and implementing a market development plan for any cancer
vaccine drug to ensure that the optimal market conditions exist by the time the product is commercialized.

Table of Content

1 Executive Summary 3
2 About Cancer Highlights' 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 BioSeeker Group's Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights'' Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 18
4.2 List of Tables 18
5 Introduction 26
5.1 The Scope of this Report 26
5.2 Definitions 29
5.3 Abbreviations 29
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment 30
6.1 Drug Repositioning in Oncology 30
6.2 Introduction to Targets of Cancer Vaccine Drugs 31
6.2.1 Acid Phosphatase Activity Targets 35
6.2.2 Carboxypeptidase Activity Targets 36
6.2.3 Catalytic Activity Targets 38
6.2.4 Cell Adhesion Molecule Activity Targets 40
6.2.5 Chaperone Activity Targets 44
6.2.6 Cofactor Binding Targets 45
6.2.7 Complement Activity Targets 47
6.2.8 Cytokine Activity Targets 49
6.2.9 DNA Binding Targets 58
6.2.10 DNA Topoisomerase Activity Targets 60
6.2.11 DNA-directed DNA Polymerase Activity Targets 61
6.2.12 Growth Factor Activity Targets 62
6.2.13 Heat Shock Protein Activity Targets 69
6.2.14 Hormone Activity Targets 70
6.2.15 Isomerase Activity Targets 71
6.2.16 Kinase Binding Targets 72
6.2.17 Kinase Regulator Activity Targets 74



6.2.18 Metallopeptidase Activity Targets 76
6.2.19 MHC Class I Receptor Activity Targets 78
6.2.20 Molecular Function Unknown Targets 79
6.2.21 Oxidoreductase Activity Targets 91
6.2.22 Peptidase Activity Targets 93
6.2.23 Peptide Hormone Targets 101
6.2.24 Protein Binding Targets 104
6.2.25 Protein Serine/Threonine Kinase Activity Targets 106
6.2.26 Protein-tyrosine Kinase Activity Targets 109
6.2.27 Receptor Activity Targets 111
6.2.28 Receptor Signaling Complex Scaffold Activity Targets 119
6.2.29 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 121
6.2.30 RNA-directed DNA Polymerase Activity Targets 122
6.2.31 Serine-type Peptidase Activity Targets 124
6.2.32 T Cell Receptor Activity Targets 127
6.2.33 Transcription Factor Activity Targets 128
6.2.34 Transcription Regulator Activity Targets 133
6.2.35 Transmembrane Receptor Activity Targets 134
6.2.36 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 135
6.2.37 Transporter Activity Targets 147
6.2.38 Other Targets 150
6.3 The Cancer Genome Project and Targets of Cancer Vaccine Drugs 157
6.3.1 Targets of Cancer Vaccine Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
157
6.4 Structure-based Drug Design in Cancer Vaccine Therapeutics is Stimulated by Available Structure Data on Biological Targets 161
6.5 Target-Target Interactions among Identified Targets of Cancer Vaccine Drugs 163
6.6 The Drug-Target Competitive Landscape 166
6.7 Protein Expression Levels of Identified Targets of Cancer Vaccine Drugs 170
6.8 Pathway Assessment of Caner Vaccine Drugs 173
6.8.1 Tools for Analysis of Cancer Pathways 174
6.8.2 Pathway Assessment 175
7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Vaccine Drugs by their Highest Stage of
Development 195
7.1 Marketed: New and Unique Drug Target Strategies of Cancer Vaccine Drugs 197
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Cancer Vaccine Drugs 197
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Cancer Vaccine Drugs 198
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Cancer Vaccine Drugs 200
7.5 Preclinical Development: New and Unique Drug Target Strategies of Cancer Vaccine Drugs 202
7.6 No Development Data: New and Unique Drug Target Strategies of Cancer Vaccine Drugs 204
7.7 Drug Target Strategies of Suspended, Discontinued or Terminated Cancer Vaccine Drugs 205
7.8 Target Strategy Profiles of Cancer Vaccine Drugs 208
7.8.1 Marketed 211
7.8.2 Phase III 212
7.8.3 Phase II 223
7.8.4 Phase I 244
7.8.5 Preclinical 255
7.8.6 Suspended 275
7.8.7 Ceased 276



7.9 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 306
8 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy 309
8.1 Small Molecules 311
8.1.1 Background 311
8.1.2 Target Strategies of Small Molecule Drugs 312
8.2 Peptide & Protein Drugs 314
8.2.2 Target Strategies of Peptide and Protein Drugs 315
8.3 Antibodies and Antibody-like Structures 321
8.3.2 Target Strategies of Antibody Drugs 321
8.4 Nucleic Acid Therapies 324
8.4.2 Target Strategies of Nucleic Acid Drugs 325
8.5 Cell & Gene Therapy 327
8.5.2 Target Strategies of Cell and Gene Therapy Drugs 328
8.6 Compound Strategies based on Sub-Cellular Localization of Drug Targets 334
9 Selecting Cancer Indications for Cancer Vaccine Drugs 339
9.1 Acute Lymphocytic Leukemia 342
9.2 Acute Myelogenous Leukemia 343
9.3 Anal Dysplasia 344
9.4 B-cell Lymphoma 344
9.5 Bladder Cancer 345
9.6 Bone Cancer 346
9.7 Brain Cancer 346
9.8 Breast Cancer 347
9.9 Cancer (general) 349
9.10 Cervical Cancer 350
9.11 Chemotherapy-induced Bone Marrow Injury (general) 351
9.12 Cervical Dysplasia 352
9.13 Chronic Myelogenous Leukemia 353
9.14 Colorectal Cancer 354
9.15 Gastrointestinal Cancer (general) 356
9.16 Gastrointestinal Stomach Cancer 356
9.17 Head and Neck Cancer 357
9.18 Hematological Cancer (general) 358
9.19 Leukemia (general) 358
9.20 Liver Cancer 359
9.21 Lung Cancer (general) 360
9.22 Lymphoma (general) 361
9.23 Melanoma 362
9.24 Mesothelioma 364
9.25 Myelodysplastic Syndrome 364
9.26 Myeloma 365
9.27 non-Hodgkin's Lymphoma 366
9.28 Non-Small Cell Lung Cancer 367
9.29 Oesophageal Cancer 369



9.30 Osteo Sarcoma 370
9.31 Ovarian Cancer 371
9.32 Pancreatic Cancer 374
9.33 Prostate Cancer 376
9.34 Renal Cancer 379
9.35 Skin Cancer (general) 381
9.36 Small Cell Lung Cancer 381
9.37 Soft Tissue Sarcoma 381
9.38 Solid Tumor 381
9.39 Squamous Cell Cancer 382
9.40 Thyroid Cancer 382
9.41 Unspecified Cancer Indication 383
9.42 Vaccine adjunct 386
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator 387
10.1 Competitive Fall-Out Assessment 387
10.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 389
10.3 AC Immune 390
10.4 Adaptimmune 392
10.5 Aduro BioTech 395
10.6 Advaxis 397
10.7 Aida Pharmaceuticals 402
10.8 Akela Pharma 404
10.9 AlphaVax 407
10.10 Apthera 410
10.11 Astellas 413
10.12 AstraZeneca 415
10.13 AVI BioPharma 418
10.14 Bavarian Nordic 421
10.15 Bellicum Pharmaceuticals 426
10.16 Biogen Idec 428
10.17 Biostar 430
10.18 BioVex 432
10.19 Cadila 434
10.20 Cancer Research Technology 436
10.21 Cell Genesys 441
10.22 Celldex Therapeutics 445
10.23 CG Therapeutics 449
10.24 Cosmo Pharmaceuticals 452
10.25 CSL 455
10.26 Dendreon 457
10.27 DeveloGen 463
10.28 Eisai 465
10.29 Eli Lilly 467
10.30 EntreMed 469
10.31 Epeius Biotechnologies 471
10.32 Generex 473
10.33 GenOdyssee Pharmaceuticals 476
10.34 GENTICEL 478



10.35 Geron 480
10.36 GlaxoSmithKline 484
10.37 Gliknik 488
10.38 GlobeImmune 490
10.39 Gradalis 493
10.40 Ichor Medical Systems 495
10.41 Idera Pharmaceuticals 497
10.42 ImmunoCellular Therapeutics 500
10.43 ImmunoFrontier 502
10.44 Immunotope 506
10.45 Innate Pharma 508
10.46 Inovio 510
10.47 Introgen Therapeutics 515
10.48 ISA Pharmaceuticals 517
10.49 Johnson & Johnson 519
10.50 Medical Marketing International 521
10.51 MediGene 524
10.52 Menarini 527
10.53 Merck KGaA 530
10.54 Micromet 532
10.55 MolMed 534
10.56 Mologen 536
10.57 Nemod Biotherapeutics 539
10.58 Neovacs 542
10.59 NIH ' US National Institute of Health 545
10.60 Non-industrial Sources 548
10.61 Northwest Biotherapeutics 554
10.62 NovaRx 556
10.63 OncoMune 559
10.64 OncoTherapy Science 561
10.65 Oncothyreon 563
10.66 Oncovir 567
10.67 Onyvax 569
10.68 Oxford BioMedica 571
10.69 Pepscan Systems 574
10.70 Pepscan Therapeutics 577
10.71 Pfizer 580
10.72 Pharmexa 582
10.73 Prima Biomed 587
10.74 Progenics Pharmaceuticals 590
10.75 Protherics 593
10.76 Radient Pharmaceuticals 595
10.77 Receptor BioLogix 597
10.78 responsif 600
10.79 Sanofi-Aventis 602
10.80 Scancell 604
10.81 SciClone Pharmaceuticals 607
10.82 TapImmune 609



10.83 Therion Biologics 611
10.84 Transgene 618
10.85 United Biomedical 622
10.86 Vaccinex 624
10.87 Vaxil BioTherapeutics 627
10.88 Vaxon Biotech 630
10.89 VaxOnco 633
10.90 Vectura 636
10.91 Vical 638
10.92 Viragen 641
10.93 Virionics 643
10.94 ViroMed 645
10.95 Zensun 648
11 Disclaimer 650
12 Drug Index 651
13 Company Index 656

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Cancer Vaccine Drugs 165
Figure 2: The Drug-Target Competitive Landscape of Cancer Vaccine Drugs - Large Cluster 167
Figure 3: The Drug-Target Competitive Landscape of Cancer Vaccine Drugs - Smaller Clusters 168
Figure 4: Head-to-Head Targeting Competitive Landscape of Cancer Vaccine Drugs 169
Figure 5: Distribution of Compound Strategies among Cancer Vaccine Drugs 334
Figure 6: Primary Sub-cellular Localization of Drug Targets 335

4.2 List of Tables
Table 1: Cancer Highlights'' Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Cancer Vaccine Drug Pipeline by Stage of Development 26
Table 3: Head to Head Target Competition among Cancer Vaccine Drugs 26
Table 4: Overview of Drug Target Strategy Themes 31
Table 5: Terminally Ceased Targets of Cancer Vaccine Drugs 32
Table 6: Official Gene Name to Target Profle 33
Table 7: Targets of Cancer Vaccine Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
158
Table 8: Identity of Cancer Vaccine Drug Targets with Available Biological Structures 161
Table 9: Number of Target-Target Interactions among Targets of Cancer Vaccine Drugs 163
Table 10: Available Protein Expression Profiles of Cancer Vaccine Drugs Targets 170
Table 11: Pathway Summary 175
Table 12: Drug Targets without any Identified Assigned Pathways 175
Table 13: Pathway Profiles According to BioCarta of Cancer Vaccine Drug Targets 177
Table 14: Pathway Profiles According to KEGG of Cancer Vaccine Drug Targets 184
Table 15: Pathway Profiles According to NetPath of Cancer Vaccine Drug Targets 193
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 195
Table 17: Top Competitive Target Strategies of Cancer Vaccine Drugs 196
Table 18: New and Unique Target Strategies of Marketed Cancer Vaccine Drugs 197
Table 19: New and Unique Target Strategies in Phase III Clinical Development of Cancer Vaccine Drugs 197
Table 20: New and Unique Target Strategies in Phase II Clinical Development of Cancer Vaccine Drugs 198
Table 21: The Competition Through Close Mechanistic Approximation Between Phase II Cancer Vaccine Drugs 199



Table 22: New and Unique Target Strategies in Phase I Clinical Development of Cancer Vaccine Drugs 200
Table 23: The Competition Through Close Mechanistic Approximation Between Phase I Cancer Vaccine Drugs 201
Table 24: New and Unique Target Strategies in Preclinical Development of Cancer Vaccine Drugs 202
Table 25: The Competition Through Close Mechanistic Approximation Between Preclinical Cancer Vaccine Drugs 203
Table 26: New and Unique Target Strategies in Unknown Developmental Stage of Cancer Vaccine Drugs 204
Table 27: The Competition Through Close Mechanistic Approximation Between Cancer Vaccine Drugs with No Developmental Data
204
Table 28: Target Strategies of Suspended, Discontinued and Terminated Cancer Vaccine Drugs 206
Table 29: Connecting Target Strategy with Its Identification Number 208
Table 30: The Competition Through Close Mechanistic Approximation Among Cancer Vaccine Drugs 306
Table 31: Overview of Compound Strategy Competition Among Cancer Vaccine Drugs 310
Table 32: Overview of the Competitive Landscape of Small Molecule Based Cancer Vaccines Drugs 312
Table 33: Pursued Target Strategies of Small Molecule Drugs Based Cancer Vaccines Drugs 313
Table 34: Overview of the Competitive Landscape of Peptide Based Cancer Vaccines Drugs 315
Table 35: Competitive Comparison of Target Strategies of Peptide Based Cancer Vaccines Drugs 316
Table 36: Pursued Target Strategies of Peptide Based Cancer Vaccines Drugs 316
Table 37: Overview of the Competitive Landscape of Protein Based Cancer Vaccines Drugs 318
Table 38: Competitive Comparison of Target Strategies of Protein Based Cancer Vaccines Drugs 319
Table 39: Pursued Target Strategies of Protein Based Cancer Vaccines Drugs 319
Table 40: Overview of the Competitive Landscape of Antibody Based Cancer Vaccines Drugs 321
Table 41: Competitive Comparison of Target Strategies of Antibody Based Cancer Vaccines Drugs 322
Table 42: Pursued Target Strategies of Antibody Based Cancer Vaccines Drugs 322
Table 43: Overview of the Competitive Landscape of Nucleic Acid Based Cancer Vaccines Drugs 325
Table 44: Pursued Target Strategies of Nucleic Acid Based Cancer Vaccines Drugs 326
Table 45: Potential Forms of Cell Therapy 327
Table 46: Vectors in Gene Therapy 328
Table 47: Overview of the Competitive Landscape of Cell Therapy Based Cancer Vaccines Drugs 328
Table 48: Competitive Comparison of Target Strategies of Cell Therapy Based Cancer Vaccine Drugs 329
Table 49: Pursued Target Strategies of Cell Therapy Based Cancer Vaccine Drugs 329
Table 50: Overview of the Competitive Landscape of Gene Therapy Based Cancer Vaccines Drugs 330
Table 51: Competitive Comparison of Target Strategies of Gene Therapy Based Cancer Vaccines Drugs 331
Table 52: Pursued Target Strategies of Gene Therapy Based Cancer Vaccines Drugs 332
Table 53: Compound Strategies based on Sub-Cellular Localization of Cancer Vaccine Drug Targets 335
Table 54 Competitive Summary by Cancer Indication of Cancer Vaccine Drugs 340
Table 55: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Acute Lymphocytic Leukemia 342
Table 56: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Acute Myelogenous Leukemia 343
Table 57: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Anal Dysplasia 344
Table 58: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of B-cell Lymphoma 344
Table 59: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Bladder Cancer 345
Table 60: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Bone Cancer 346
Table 61: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Brain Cancer 346
Table 62: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Breast Cancer 347
Table 63: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 348
Table 64: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cancer (general) 349
Table 65: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cervical Cancer 350
Table 66: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 351
Table 67: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Chemotherapy-induced Bone Marrow
Injury (general) 351



Table 68: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cervical Dysplasia 352
Table 69: The Competition through Close Mechanistic Approximation between Cervical Dysplasia Drugs 353
Table 70: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Chronic Myelogenous Leukemia 353
Table 71: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Colorectal Cancer 354
Table 72: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 355
Table 73: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Gastrointestinal Cancer (general) 356
Table 74: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Gastrointestinal Stomach Cancer 356
Table 75: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Head and Neck Cancer 357
Table 76: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 357
Table 77: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Hematological Cancer (general) 358
Table 78: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Leukemia (general) 358
Table 79: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Liver Cancer 359
Table 80: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 359
Table 81: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Lung Cancer (general) 360
Table 82: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 361
Table 83: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Lymphoma (general) 361
Table 84: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Melanoma 362
Table 85: The Competition through Close Mechanistic Approximation between Melanoma Drugs 363
Table 86: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Mesothelioma 364
Table 87: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Myelodysplastic Syndrome 364
Table 88: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Myeloma 365
Table 89: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of non-Hodgkin's Lymphoma 366
Table 90: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Non-Small Cell Lung Cancer 367
Table 91: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 368
Table 92: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Oesophageal Cancer 369
Table 93: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Osteo Sarcoma 370
Table 94: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Ovarian Cancer 371
Table 95: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 373
Table 96: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Pancreatic Cancer 374
Table 97: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 375
Table 98: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Prostate Cancer 376
Table 99: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 377
Table 100: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Renal Cancer 379
Table 101: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 380
Table 102: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Skin Cancer (general) 381
Table 103: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Small Cell Lung Cancer 381
Table 104: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Soft Tissue Sarcoma 381
Table 105: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Solid Tumor 381
Table 106: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Squamous Cell Cancer 382
Table 107: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Thyroid Cancer 382
Table 108: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Unspecified Cancer Indication 383
Table 109: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs 384
Table 110: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Vaccine adjunct 386
Table 111: Example of a Competitive Fall-Out Table (Modified, Platelet glycoprotein 4 trageting drugs) 388
Table 112: Summary Table of Corporate Changes in the Competitive Landscape of Cancer Vaccine Drug Development 389
Table 113: AC Immune's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 390
Table 114: Adaptimmune's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 392
Table 115: Aduro BioTech's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 395



Table 116: Advaxis' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 397
Table 117: Aida Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 402
Table 118: Akela Pharma's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 404
Table 119: AlphaVax's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 407
Table 120: Apthera's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 410
Table 121: Astellas' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 413
Table 122: AstraZeneca's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 415
Table 123: AVI BioPharma's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 418
Table 124: Bavarian Nordic's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 421
Table 125: Bellicum Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 426
Table 126: Biogen Idec's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 428
Table 127: Biostar's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 430
Table 128: BioVex's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 432
Table 129: Cadila's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 434
Table 130: Cancer Research Technology's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 436
Table 131: Cell Genesys' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 441
Table 132: Celldex Therapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 445
Table 133: CG Therapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 449
Table 134: Cosmo Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 452
Table 135: CSL's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 455
Table 136: Dendreon's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 457
Table 137: DeveloGen's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 463
Table 138: Eisai's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 465
Table 139: Eli Lilly's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 467
Table 140: EntreMed's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 469
Table 141: Epeius Biotechnologies' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 471
Table 142: Generex's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 473
Table 143: GenOdyssee Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 476
Table 144: GENTICEL's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 478
Table 145: Geron's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 480
Table 146: GlaxoSmithKline's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 484
Table 147: Gliknik's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 488
Table 148: GlobeImmune's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 490
Table 149: Gradalis' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 493
Table 150: Ichor Medical Systems' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 495
Table 151: Idera Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 497
Table 152: ImmunoCellular Therapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 500
Table 153: ImmunoFrontier's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 502
Table 154: Immunotope's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 506
Table 155: Innate Pharma's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 508
Table 156: Inovio's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 510
Table 157: Introgen Therapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 515
Table 158: ISA Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 517
Table 159: Johnson & Johnson's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 519
Table 160: Medical Marketing International's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 521
Table 161: MediGene's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 524
Table 162: Menarini's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 527
Table 163: Merck KGaA's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 530



Table 164: Micromet's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 532
Table 165: MolMed's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 534
Table 166: Mologen's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 536
Table 167: Nemod Biotherapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 539
Table 168: Neovacs' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 542
Table 169: NIH's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 545
Table 170: Non-industrial Sources' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 548
Table 171: Northwest Biotherapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 554
Table 172: NovaRx's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 556
Table 173: OncoMune's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 559
Table 174: OncoTherapy Science's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 561
Table 175: Oncothyreon's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 563
Table 176: Oncovir's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 567
Table 177: Onyvax's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 569
Table 178: Oxford BioMedica's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 571
Table 179: Pepscan Systems' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 574
Table 180: Pepscan Therapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 577
Table 181: Pfizer's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 580
Table 182: Pharmexa's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 582
Table 183: Prima Biomed's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 587
Table 184: Progenics Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 590
Table 185: Protherics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 593
Table 186: Radient Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 595
Table 187: Receptor BioLogix's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 597
Table 188: responsif's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 600
Table 189: Sanofi-Aventis' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 602
Table 190: Scancell's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 604
Table 191: SciClone Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 607
Table 192: TapImmune's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 609
Table 193: Therion Biologics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 611
Table 194: Transgene's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 618
Table 195: United Biomedical's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 622
Table 196: Vaccinex's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 624
Table 197: Vaxil BioTherapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 627
Table 198: Vaxon Biotech's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 630
Table 199: VaxOnco's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 633
Table 200: Vectura's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 636
Table 201: Vical's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 638
Table 202: Viragen's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 641
Table 203: Virionics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 643
Table 204: ViroMed's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 645
Table 205: Zensun's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 648


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline

Product Formats
Please select the product formats and the quantity you require.

Digital Copy--USD 2 729.99 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline